

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: VITE et al.

Application No.: 09/084,542

Filed: May 26, 1998

For: EPOTHILONE DERIVATIVES

Group Art Unit: 1624

Examiner: B. Kifle

Attorney Docket No.: LD125b (5624-263)

TECH CENTER 1600/2900


OCT 31 2001

RECEIVED

#19 D

PS

11/21/01



**PRELIMINARY AMENDMENT**

**Box Non-Fee Amendment**

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

In response to the Office Action mailed August 29, 2001, Applicants are concurrently filing herewith a Request for Continued Examination and this amendment. Prior to any further action in connection with the above-identified application, please enter the following amendments, remarks, and Information Disclosure Statement filed on September 28, 2001. Applicants respectfully request reconsideration of the pending claims and allowance thereof.

**IN THE SPECIFICATION**

Marked up versions of all revised paragraphs showing insertions and deletions are included in Appendix A.

Replace the paragraph at page 8, line 20 to page 9, line 11 with the following text:

--The compounds of formula V are microtubule-stabilizing agents. They are thus useful in the treatment of a variety of cancers or other abnormal proliferative diseases, including (but not limited to) the following;

- carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin; including squamous cell carcinoma;
- hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and Burketts lymphoma;

609

J